ExactScience

Healthcare

ExactScience

Transforming Cancer Care Through Personalized Diagnostics

Average rated: 0.00/5 with 0 ratings

Favorited 0 times

Rate this tool

Visit
Explore more top AI tools

About ExactScience

Exact Sciences Corp. is a prominent American molecular diagnostics company based in Madison, Wisconsin, dedicated to advancing cancer care. Its primary mission is to eradicate cancer through prevention, early detection, and personalized treatment guidance. This ambitious goal is achieved with a diverse product portfolio that spans the entire cancer care continuum, from hereditary cancer risk assessment to screening, prognosis evaluation, and therapy selection. The company's key offerings include a variety of innovative diagnostic tests. One of its flagship products, **Cologuard®**, is a non-invasive colorectal cancer screening test designed to detect abnormal DNA and blood in stool samples. The FDA has approved its use for individuals aged 45 and older. Exact Sciences has further enhanced this product line with the launch of Cologuard Plus™, also FDA-approved. Additionally, the **Oncotype DX® tests** analyze gene expression in tumors to predict cancer recurrence and guide treatment decisions, particularly for breast and colon cancers. The **OncoExTra®** test provides comprehensive genomic profiling to help inform cancer treatment strategies, while **Oncoguard® Liver** offers early detection of hepatocellular carcinoma through a blood sample. **Riskguard™**, another of their key services, assesses hereditary cancer risk using blood or saliva samples. Exact Sciences is also pioneering the development of blood-based multi-cancer early detection (MCED) tests, with recent studies demonstrating promising results for blood-based colorectal cancer screening. The ASCEND-2 study confirmed high detection rates and specificity for the most aggressive cancers through a multi-biomarker approach, highlighting the company’s commitment to scientific validation and innovation. These tests are widely used in healthcare to screen for cancer, assess hereditary cancer risk, guide personalized treatment decisions based on tumor genomics, and monitor for cancer recurrence. The comprehensive nature of Exact Sciences' portfolio, along with its continuous investment in research and development, positions it as a leader in its field. The ExactNexus™ technology platform enhances the integration of their tests into healthcare workflows, facilitating electronic ordering and seamless result reporting. Exact Sciences has gained significant recognition, being certified as a Great Place to Work® for six consecutive years. Its tests have also been endorsed within major clinical guidelines and quality measures, underscoring their clinical validity. Recent advancements include the publication of results from the BLUE-C study, validating the next-generation Cologuard® test, and the launch of the OncoExTra® test. Their acquisition of PreventionGenetics enhances capabilities in hereditary cancer testing. Furthermore, their innovative research has been showcased at recent medical conferences like ESMO 2024, demonstrating their ongoing commitment to improving cancer care through technology and innovation.

Key Features

  • Comprehensive suite of cancer tests across the care continuum, including early detection and screening.
  • Offers Cologuard®, a non-invasive at-home stool DNA test for colorectal cancer screening.
  • Develops blood tests like Oncoguard® Liver for early detection of hepatocellular carcinoma and Riskguard™ for hereditary cancer risk assessment.
  • Provides advanced tests still in development, such as Cancerguard™ for multiple cancer detection.
  • Treatment guidance through tests like Oncotype DX Breast and Colon Recurrence Scores for assessing cancer recurrence and therapy benefits.
  • OncoExTra® test for aiding late-stage cancer therapy selection.
  • Supports patient and provider through logins for test ordering and results tracking.
  • Backed by extensive scientific research, publications, and clinical studies.
  • Engages in community outreach and health equity initiatives.

Tags

molecular diagnosticscancer carepreventionearly detectiontreatment guidancenon-invasive screening testscolorectal cancergenomic profilinghereditary cancer riskmulti-cancer early detectioninnovationscientific validationclinical guidelines

FAQs

What is Cologuard®, and who is it for?
Cologuard® is a non-invasive, at-home stool test that screens for colorectal cancer in adults 45 years and older who are at average risk. It is a prescription-only test.
How does the Oncoguard® Liver test work, and what type of cancer does it detect?
The Oncoguard® Liver test is a blood test designed to detect hepatocellular carcinoma, the most common type of liver cancer, in individuals with cirrhosis or chronic hepatitis B. It uses a panel of DNA and protein markers for early-stage detection.
What cancers does the Riskguard™ test screen for, and what type of sample is needed?
Riskguard™ is a hereditary cancer test that screens for genetic changes associated with an increased risk of ten common cancers. A simple blood or saliva sample is required.
What is the Cancerguard™ test, and what stage of cancer does it aim to detect?
Cancerguard™ is a blood test under development that aims to detect multiple cancers in their earliest stages from a single blood draw.
What is Oncotype DX, and what types of cancer does it cover?
Oncotype DX is a suite of tumor-tissue tests providing treatment guidance, particularly for breast and colorectal cancers. It includes tests like the DCIS Score® and Recurrence Score®.
What is OncoExTra®, and for what type of cancer patients is it intended?
OncoExTra® is a genomic test analyzing both DNA and RNA from a tumor sample, tailored for patients with advanced, metastatic, or aggressive cancers.
What is the difference between screening and surveillance tests?
Screening tests, such as Cologuard®, are used to detect cancer before symptoms appear in individuals with average risk. Surveillance tests, like Oncoguard® Liver, are focused on finding cancer in high-risk individuals.
Are Exact Sciences' tests covered by insurance?
Many tests are covered by Medicare and various commercial insurance plans, but coverage can vary. It's advisable to check with your insurance provider.
What is the process for ordering and receiving results for Exact Sciences tests?
Tests can be ordered through the Exact Sciences website or a healthcare provider. Results are usually sent to the doctor, who will discuss them with the patient.
Where can I find more information about Exact Sciences' tests?
Detailed information is available on the Exact Sciences website, which includes test indications, results interpretation, and customer support contacts.